Vanda's Atypical Approval: Is It Time to Rethink Attitudes Toward FDA?
This article was originally published in RPM Report
Executive Summary
The atypical antipsychotic iloperidone took a treacherous route to market. What does FDA’s decision-making from not approvable to approval in 10 months say about approval standards?
You may also be interested in...
The FDA Roundtable Part I: The Regulators' View of Drug Development
Three top FDA officials sat down with The RPM Report at their White Oak campus to discuss the top drug regulatory issues. On the table for discussion: drug safety, comparative effectiveness and the future of drug development.
FDAAA Pays Off: Drug Safety Controls Bring Immediate Returns to Sponsors
Companies as diverse as CV Therapeutics, UCB, GSK, Pozen and Biovail are all smiles about becoming unwitting guinea pigs in the new era of drug safety. None could have expected to be pioneers in facing new post-marketing burdens-but all are thrilled that their products were approved at all. And most have seen an immediate payback for their investors.
US Medicare Plans 'Can' Cover Wegovy, CMS Says, But Will They?
Medicare is making clear that Part D ‘can’ cover GLP-1 inhibitors that are approved for cardiovascular indications – but in language that seems to leave plans considerable discretion for now. The formulary review process for 2025 may be a more important milestone for changes.